{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:44Z","timestamp":1792788104870,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005273","name":"Yunnan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.09.039","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:19:22Z","timestamp":1791501562000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained relief of chronic pain via a Nav1.7-targeting ASO-siRNA conjugate in rats"],"prefix":"10.1016","author":[{"given":"Bin","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangchuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8396-9398","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4302-9977","authenticated-orcid":false,"given":"Jianming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-1765","authenticated-orcid":false,"given":"Guohao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.09.039_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.09.039_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ejp.2234","article-title":"The costs of chronic pain\u2013Long-term estimates","volume":"28","author":"Stubhaug","year":"2024","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076036","article-title":"Chronic pain: definitions and diagnosis","volume":"381","author":"Kang","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.09.039_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid Abuse in Chronic Pain \u2014 Misconceptions and Mitigation Strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2026.09.039_bib6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ejp.1736","article-title":"European\u2217 clinical practice recommendations on opioids for chronic noncancer pain \u2013 Part 1: Role of opioids in the management of chronic noncancer pain","volume":"25","author":"H\u00e4user","year":"2021","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj9837","article-title":"Developing nociceptor-selective treatments for acute and chronic pain","volume":"13","author":"Jayakar","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib8","first-page":"1085","article-title":"Suzetrigine, a Nonopioid Nav1.8 Inhibitor for Treatment of Moderate to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ymthe.2026.09.039_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The Role of Voltage-Gated Sodium Channels in Pain Signaling","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2026.09.039_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41583-021-00444-w","article-title":"The physiological function of different voltage-gated sodium channels in pain","volume":"22","author":"Goodwin","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2026.09.039_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJMe2305708","article-title":"Targeting a Peripheral Sodium Channel to Treat Pain","volume":"389","author":"Waxman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.039_bib13","doi-asserted-by":"crossref","first-page":"E1670","DOI":"10.1002\/humu.21325","article-title":"Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations","volume":"31","author":"Cox","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2026.09.039_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pain.2009.02.016","article-title":"Two novel SCN9A mutations causing insensitivity to pain","volume":"143","author":"Nilsen","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jmg.2003.012153","article-title":"Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia","volume":"41","author":"Yang","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.09.039_bib16","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/brain\/awh514","article-title":"Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons","volume":"128","author":"Dib-Hajj","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuron.2006.10.006","article-title":"SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes","volume":"52","author":"Fertleman","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2026.09.039_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ana.22485","article-title":"Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy","volume":"71","author":"Faber","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pharmthera.2016.11.015","article-title":"Nav1.7 as a pain target \u2013 From gene to pharmacology","volume":"172","author":"Vetter","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-020-00415-2","article-title":"Status of peripheral sodium channel blockers for non-addictive pain treatment","volume":"16","author":"Alsaloum","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-024-01108-x","article-title":"Voltage-gated sodium channels in excitable cells as drug targets","volume":"24","author":"Alsaloum","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib22","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2147\/JPR.S247182","article-title":"Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia","volume":"13","author":"Kotecha","year":"2020","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ymthe.2026.09.039_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","article-title":"Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial","volume":"16","author":"Zakrzewska","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib24","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"McDonnell","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib25","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1111\/bph.15327","article-title":"Fifteen years of Nav1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?","volume":"179","author":"Eagles","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1359-6446(00)01570-1","article-title":"Voltage-gated sodium channels as therapeutic targets","volume":"5","author":"Clare","year":"2000","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.09.039_bib27","first-page":"314","article-title":"Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison","volume":"6","author":"Loussouarn","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1474-4422(14)70024-9","article-title":"Painful and painless channelopathies","volume":"13","author":"Bennett","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-022-00365-7","article-title":"Genetic pain loss disorders","volume":"8","author":"Lischka","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.09.039_bib30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2026.09.039_bib34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","article-title":"Frameworks for transformational breakthroughs in RNA-based medicines","volume":"23","author":"Androsavich","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41392-024-02035-4","article-title":"Nucleic acid drugs: recent progress and future perspectives","volume":"9","author":"Sun","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib38","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1021\/acs.jmedchem.4c02528","article-title":"Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver","volume":"68","author":"Anand","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.09.039_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molmed.2023.10.005","article-title":"Three \u2018E\u2019 challenges for siRNA drug development","volume":"30","author":"Guo","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00109-005-0021-5","article-title":"Isoform-specific silencing of the Livin gene by RNA interference defines Livin \u03b2 as key mediator of apoptosis inhibition in HeLa cells","volume":"84","author":"Crnkovi\u0107-Mertens","year":"2006","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib42","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.09.039_bib43","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington\u2019s disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.039_bib44","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.09.039_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib46","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib48","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/j.pain.0000000000001074","article-title":"Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain","volume":"159","author":"Mohan","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/nat.2022.0067","article-title":"Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response","volume":"33","author":"Pollak","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/nat.2022.0033","article-title":"Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells","volume":"32","author":"Burel","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","article-title":"A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides","volume":"10","author":"Dieckmann","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.09.039_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.09.039_bib57","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkn902","article-title":"Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based on-target effect","volume":"36","author":"Ui-Tei","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.09.039_bib58","first-page":"35","article-title":"Segmental spinal nerve ligation model of neuropathic pain","volume":"99","author":"Chung","year":"2004","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/bjp.2008.259","article-title":"Effects of pregabalin on visceral pain responses and colonic compliance in rats","volume":"155","author":"Ravnefjord","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib61","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.09.039_bib63","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/embor.2012.82","article-title":"Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells","volume":"13","author":"B\u00e9thune","year":"2012","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ymthe.2026.09.039_bib64","doi-asserted-by":"crossref","first-page":"46234","DOI":"10.1074\/jbc.M406387200","article-title":"Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia","volume":"279","author":"Raymond","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.039_bib65","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.039_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular Mechanisms of Antisense Oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.09.039_bib67","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 Is the Catalytic Engine of Mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.09.039_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-22380-3_2","article-title":"The microRNA machinery","volume":"887","author":"Roberts","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib69","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nsmb.2607","article-title":"Molecular dissection of human Argonaute proteins by DNA shuffling","volume":"20","author":"Sch\u00fcrmann","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib70","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.molcel.2026.04.029","article-title":"Structural basis for RISC assembly of human Argonaute2","volume":"86","author":"Zhang","year":"2026","journal-title":"Mol. Cel"},{"key":"10.1016\/j.ymthe.2026.09.039_bib71","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1093\/nar\/gkae260","article-title":"Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo","volume":"52","author":"Sarli","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.09.039_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102757","article-title":"SCAD: A Modular Platform for Efficient Delivery of Duplex RNA to the CNS and Beyond","volume":"36","author":"Kang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.09.039_bib73","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1523\/JNEUROSCI.1049-18.2018","article-title":"Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors","volume":"38","author":"Shields","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2026.09.039_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuroscience.2018.05.017","article-title":"Sex Differences and Estrous Cycle Effects of Peripheral Serotonin-Evoked Rodent Pain Behaviors","volume":"384","author":"Kaur","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2026.09.039_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13293-016-0086-6","article-title":"Estrous cycle influences excitatory amino acid transport and visceral pain sensitivity in the rat: effects of early-life stress","volume":"7","author":"Moloney","year":"2016","journal-title":"Biol. Sex. Differ."},{"key":"10.1016\/j.ymthe.2026.09.039_bib76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaneurol.2025.4946","article-title":"Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis","volume":"83","author":"Miller","year":"2026","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.09.039_bib77","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.039_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102437","article-title":"Development, opportunities, and challenges of siRNA nucleic acid drugs","volume":"36","author":"Xiao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.09.039_bib79","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/s41467-024-52352-z","article-title":"Erythropoietin regulates energy metabolism through EPO-EpoR-RUNX1 axis","volume":"15","author":"Yin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.039_bib80","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/mtna.2012.6","article-title":"Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3\u2032 Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs","volume":"1","author":"Zhou","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.09.039_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneumeth.2011.04.021","article-title":"Direct injection into the dorsal root ganglion: Technical, behavioral, and histological observations","volume":"199","author":"Fischer","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.ymthe.2026.09.039_bib82","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1016\/j.cell.2024.09.006","article-title":"The TMEM132B-GABAA receptor complex controls alcohol actions in the brain","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.039_bib83","first-page":"1065","article-title":"Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain","volume":"118","author":"Z\u00f6llner","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.09.039_bib84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1744-8069-3-21","article-title":"Delayed Sympathetic Dependence in the Spared Nerve Injury (SNI) Model of Neuropathic Pain","volume":"3","author":"Pertin","year":"2007","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3959(88)90026-7","article-title":"A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia","volume":"32","author":"Hargreaves","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.09.039_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01445-23","article-title":"Heterogeneous lineage-specific arginine deiminase expression within dental microbiome species","volume":"12","author":"Mann","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ymthe.2026.09.039_bib87","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.ymthe.2026.09.039_bib88","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: Improving the clinical safety of GalNAc\u2013siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:20:35Z","timestamp":1792786835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":88,"alternative-id":["S1525001626008579"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.039","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained relief of chronic pain via a Nav1.7-targeting ASO-siRNA conjugate in rats","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}